Advanced search
Publication Cover
Biomarkers Volume 23, 2018 - Issue 4
Submit an article Journal homepage
1,922
Views
12
CrossRef citations to date
0
Altmetric
Research Article

NTproBNP and ST2 as predictors for all-cause and cardiovascular mortality in elderly patients with symptoms suggestive for heart failure

Kurt BomanResearch Unit, Department of Medicine, Skellefteå Hospital, Skellefteå, Sweden; ;Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Correspondence[email protected]
,
Finn Thormark FröstDepartment of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
,
Ann-Charlotte R. BergmanDepartment of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
&
Mona OlofssonResearch Unit, Department of Medicine, Skellefteå Hospital, Skellefteå, Sweden;
Pages 373-379 | Received 03 Oct 2017, Accepted 11 Jan 2018, Published online: 06 Feb 2018

References

  • Aimo, A., et al., 2017. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC heart faiurel, 5 (4), 287–296.
  • Ather, S., et al., 2012. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. Journal of the American college of cardiology, 59 (11), 998–1005.
  • Benjamin, E.J., et al., 1992. Determinants of doppler indexes of left ventricular diastolic function in normal subjects (the Framingham heart study). The American journal of cardiology, 70 (4), 508–515.
  • Chen, W. and Frangogiannis, N.G., 2010. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart failure reviews, 15 (5), 415–422.
  • Daniels, L.B., et al., 2010. Association of ST2 levels with cardiac structure and function and mortality in outpatients. American heart journal, 160 (4), 721–728.
  • de Boer, R.A., et al., 2015. State of the art: newer biomarkers in heart failure. European journal of heart failure, 17 (6), 559–569.
  • Doust, J.A., et al., 2005. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ, 330 (7492), 625.
  • Gül, İ., et al., 2017. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure. Anatolian journal of cardiology, 18 (3), 200–205.
  • Maisel, A.S., et al., 2004. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. American heart journal, 147 (6), 1078–1084.
  • Manzano, L., et al., 2011. Predictors of clinical outcomes in elderly patients with heart failure. European journal of heart failure, 13 (5), 528–536.
  • Meijers, W.C., van der Velde, A.R., and de Boer, R.A., 2016. ST2 and Galectin-3: ready for prime time? International federation of clinical chemistry and laboratory medicine, 27 (3), 238–252.
  • Olofsson, M. and Boman, K., 2010. Usefulness of natriuretic peptides in primary health care: an exploratory study in elderly patients. Scandinavian journal of primary health care, 28 (1), 29–35.
  • Olofsson, M. and Boman, K., 2015. Impact on mortality of systolic and diastolic heart failure in the elderly: 10 years of follow up. Journal of clinical gerontology & geriatrics, 6, 20–26.
  • Olofsson, M., Edebro, D., and Boman, K., 2007. Are elderly patients with suspected HF misdiagnosed? A primary health care center study. Cardiology, 107 (4), 226–232.
  • Parikh, R.H., et al., 2016. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. Journal of the American heart association, 5 (8), e003188.
  • Pascual-Figal, D.A., et al., 2009. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. Journal of the American college of cardiology, 54 (23), 2174–2179.
  • Ponikowski, P., et al., 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure, 18 (8), 891–975.
  • Remme, W.J., and Swedberg, K., Task Force for the D, Treatment of Chronic Heart Failure ESoC, 2001. Guidelines for the diagnosis and treatment of chronic heart failure. European heart journal, 22 (17), 1527–1560.
  • Roche Diagnostic Corporations, 2002. 11/12/02 51 O (k) Summary, K022516-Elecsys ProBNP. NOV 1 9 2002 Introduction.
  • Ryden-Bergsten, T. and Andersson, F., 1999. The health care costs of heart failure in Sweden. Journal of internal medicine, 246 (3), 275–284.
  • Sanada, S., et al., 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. The journal of clinical investigation, 117 (6), 1538–1549.
  • Stewart, S., et al., 2001. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. European journal of heart failure, 3 (3), 315–322.
  • Wang, Y.C., et al., 2013. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. Journal of cardiac failure, 19 (3), 163–168.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.